Volume | 2,128,216 |
|
|||||
News | - | ||||||
Day High | 27.695 | Low High |
|||||
Day Low | 27.085 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Royalty Pharma PLC | RPRX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
27.33 | 27.085 | 27.695 | 27.17 | 27.48 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
23,302 | 2,128,216 | $ 27.38 | $ 58,266,676 | - | 25.92 - 34.65 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:55:01 | 10 | $ 27.10 | USD |
Royalty Pharma PLC Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
16.23B | 597.43M | - | 2.35B | 1.13B | 1.90 | 14.30 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Royalty Pharma News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RPRX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 28.39 | 28.49 | 27.085 | 27.80 | 2,187,542 | -1.20 | -4.23% |
1 Month | 27.84 | 28.99 | 27.085 | 28.08 | 2,916,176 | -0.65 | -2.33% |
3 Months | 31.42 | 31.655 | 27.085 | 29.00 | 2,613,788 | -4.23 | -13.46% |
6 Months | 26.91 | 31.655 | 26.56 | 28.84 | 2,699,385 | 0.28 | 1.04% |
1 Year | 33.82 | 34.65 | 25.92 | 29.22 | 2,507,372 | -6.63 | -19.60% |
3 Years | 40.66 | 47.10 | 25.92 | 35.79 | 2,150,079 | -13.47 | -33.13% |
5 Years | 45.90 | 57.50 | 25.92 | 38.05 | 2,147,104 | -18.71 | -40.76% |
Royalty Pharma Description
Royalty Pharma PLC is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The company assembles a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's therapies, which includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Johnson & Johnson's Tremfya, Gilead's Trodelvy, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates. |